PMID

Data

Article Title

Organization

Perspective: Tyrosine phosphatases as novel targets for antiplatelet therapy.

Sanford-Burnham Medical Research Institute

Dual-Specificity Phosphatase CDC25A/B Inhibitor Identified from a Focused Library with Nonelectrophilic Core Structure.

TBA

Arylstibonic acids are potent and isoform-selective inhibitors of Cdc25a and Cdc25b phosphatases.

Imperial College

Identification and characterization of novel inhibitors of mPTPB, an essential virulent phosphatase from Mycobacterium tuberculosis.

Indiana University School of Medicine

Inhibition of the Hematopoietic Protein Tyrosine Phosphatase by Phenoxyacetic Acids.

Sanford-Burnham Medical Research Institute

Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages.

University of Pittsburgh

Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases.

Virginia Polytechnic Institute and State University

Structure-Based Design of Active-Site-Directed, Highly Potent, Selective, and Orally Bioavailable Low-Molecular-Weight Protein Tyrosine Phosphatase Inhibitors.

Eli Lilly

Inhibition of Low Molecular Weight Protein Tyrosine Phosphatase by an Induced-Fit Mechanism.

Purdue University

Highly Potent and Selective

Purdue University

Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment.

Chinese Academy of Sciences

Pyrimidone carboxamide compounds as PDE2 inhibitors

Merck Sharp & Dohme

Pyrimidine compounds as mTOR and PI3K inhibitors

Development Center For Biotechnology

Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors

Abbvie

1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as P38 MAP knase inhibitors

Respivert

Structure-function relationship of the inhibition of the 3,5,3'-triiodothyronine binding to the alpha1- and beta1-thyroid hormone receptor by amiodarone analogs.

University of Amsterdam

p38 MAP kinase inhibitors. Part 6: 2-arylpyridazin-3-ones as templates for inhibitor design.

Merck Research Laboratories

Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.

Takeda Pharmaceutical

Factorizing selectivity determinants of inhibitor binding toward aldose and aldehyde reductases: structural and thermodynamic properties of the aldose reductase mutant Leu300Pro-fidarestat complex.

Institute of Genetics and Molecular and Cellular Biology (Igbmc)